TBPH Q2 2024 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+3.7% YoY

Gross Profit

$4M30.2% margin

Operating Income

-$16M-110.2% margin

Net Income

-$17M-115.9% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-1.7%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$362M

Total Liabilities

$168M

Stockholders' Equity

$194M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$14M	+3.7%
Gross Profit	$4M	$4M	-0.5%
Operating Income	-$16M	-$16M	+2.6%
Net Income	-$17M	-$16M	-5.7%

Revenue Segments

YUPELRI Monotherapy

$19M57%

Collaboration revenue

$14M43%